News & Updates

First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.

The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.

Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.

Once-only screening with flexible sigmoidoscopy appears to provide prolonged protection against colorectal cancer (CRC), reducing both incidence and mortality rates for up to 2 decades, according to the updated results of the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Machine learning models can predict patients with new-onset diabetes who are at greater risk for developing pancreatic cancer, a study has shown.

Patients with coeliac disease (CD) on a gluten-free diet and are treated with antiobesity medications (AOMs) show comparable weight loss outcomes to those without CD, reports a study.